US 12,473,362 B2
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
Yang Liu, Washington, DC (US); Pan Zheng, Washington, DC (US); and Martin Devenport, Gaithersburg, MD (US)
Assigned to OncoC4, Inc., Rockville, MD (US)
Filed by OncoC4, Inc., Rockville, MD (US)
Filed on Mar. 22, 2023, as Appl. No. 18/188,098.
Application 18/188,098 is a division of application No. 16/803,972, filed on Feb. 27, 2020, granted, now 11,629,188.
Application 16/803,972 is a division of application No. 16/062,350, granted, now 10,618,960, issued on Apr. 14, 2020, previously published as PCT/US2016/066698, filed on Dec. 14, 2016.
Claims priority of provisional application 62/359,036, filed on Jul. 6, 2016.
Claims priority of provisional application 62/309,169, filed on Mar. 16, 2016.
Claims priority of provisional application 62/267,735, filed on Dec. 15, 2015.
Prior Publication US 2023/0391870 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61K 39/00 (2013.01); A61P 35/00 (2018.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/575 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 12 Claims
 
1. A method of treating melanoma in a subject in need thereof, comprising administering a composition comprising an anti-CTLA4 antibody or an antigen binding fragment thereof to the subject, wherein the anti-CTLA4 antibody or the antigen binding fragment is capable of binding to a human CTLA4 protein and comprises:
(a) a light chain variable region comprising: (i) a complementarity determining region (CDR) 1 comprising the amino acid sequence set forth in SEQ ID NO: 21; (ii) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 36, 37 or 38; and, (iii) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 23; and,
(b) a heavy chain variable region comprising: (i) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 24; (ii) a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 33, 34 or 35; and, (iii) a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 26.